naproxen has been researched along with Cholestasis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kruhlak, NL; Zhu, X | 1 |
| Ash, MM; Jolly, PS | 1 |
| Held, H | 1 |
| Calvo, MV; Diez, JL; Dominguez-Gil, A; Macias, JG | 1 |
1 review(s) available for naproxen and Cholestasis
| Article | Year |
|---|---|
Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.
Topics: Aged; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Basal Cell; Chemical and Drug Induced Liver Injury; Cholestasis; Drug Interactions; Dysgeusia; Humans; Male; Myalgia; Naproxen; Pyridines; Skin Neoplasms | 2015 |
3 other study(ies) available for naproxen and Cholestasis
| Article | Year |
|---|---|
Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.
Topics: Algorithms; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Bile Duct Diseases; Calibration; Chemical and Drug Induced Liver Injury; Cholestasis; Data Mining; Databases, Factual; Drug Labeling; Endpoint Determination; Humans; Levofloxacin; Liver; Naproxen; Product Surveillance, Postmarketing; Quantitative Structure-Activity Relationship; Toxicity Tests; Vitamins | 2014 |
[Serum protein binding and elimination half-lives of naproxen in patients with hepatocellular or obstructive icterus (author's transl)].
Topics: Adult; Aged; Blood Proteins; Cholestasis; Female; Half-Life; Humans; Jaundice; Kinetics; Male; Middle Aged; Naproxen; Protein Binding | 1980 |
Naproxen disposition in hepatic and biliary disorders.
Topics: Cholestasis; Half-Life; Humans; Kinetics; Liver Diseases; Liver Function Tests; Naproxen | 1980 |